Dr. Peter Mundel is a professor in the Nephrology and Hypertension Division at the Miller School of Medicine, University of Miami. Dr. Mundel is also the director of the Miami Institute of Renal Medicine. In 2003, he was awarded the esteemed American Society of Nephrology Young Investigator Award. Dr. Mundel is a member of numerous scientific organizations, including the American Society of Clinical Investigation and the American Society of Nephrology.
In August of 2008, Dr. Mundel, along with other esteemed physician- scientists, discovered a critical pathway of a commonly used immunosuppressant drug, cyclosporine. This discovery will make it possible to identify drugs that hold the benefits of cyclosporine in treating kidney disease, without its long-term side effects. These effects include, but aren’t limited to, the loss of kidney function itself.
Dr. Mundel attended medical school at the University of Heidelberg, in Germany. He completed a Postdoctoral Research Fellowship in the program “Experimental Kidney and Circulation Research” at the University of Heidelberg, which was funded by the German Research Foundation. He is also the author or co-author of over 86 original research articles. Dr. Mundel’s focus is on the makeup and function of podocytes, key cells found in each of the one million separate filtration units packed into a single human kidney.
Selected Publications:
Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P (2006)
Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA
signalling. Nature Cell Biol Apr 16; [Epub ahead of print]
Huber TB, Kwoh C, Wu H, Asanuma K, Gödel M, Blumer KJ, Jeffrey Miner JH, Mundel P, Shaw AS (2006). A bigenic mouse model of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn and Synaptopodin. JClin Invest. 2006, 116: 1337-1345. Epub 2006 Apr 20.
Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, Remuzzi G (2006) Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006: 168: 1073-1085 |
